Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC

About a month ago, upon touting new oncology data, Merck reaffirmed its commitment to exploring new Keytruda combinations for lung cancer patients. The Big Pharma has now pulled the plug on one of those combinations, after interim data showed an increased risk and no reward.